Soleno Therapeutics (SLNO) Preferred Stock Liabilities (2013 - 2016)
Soleno Therapeutics (SLNO) reported Preferred Stock Liabilities of $13.0 for Q4 2016, down 100.0% on a QoQ basis from $1.5 million in Q3 2014.
Soleno Therapeutics (SLNO) has 3 years of Preferred Stock Liabilities data on file, last reported at $13.0 in Q4 2016.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $13.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $13.0 (changed N/A YoY) and the FY2016 annual result came in at $13.0, changed N/A from the prior year.
- Preferred Stock Liabilities fell to $13.0 in Q4 2016 per SLNO's latest filing, from $1.5 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $6.9 million in Q4 2013 and bottomed at $13.0 in Q4 2016.
- The 3-year median for Preferred Stock Liabilities is $1.5 million (2014), against an average of $2.8 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 13.00 |
| Sep 30, 2014 | 1.50 Mn |
| Dec 31, 2013 | 6.86 Mn |